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Tamoxifen and related compounds decrease membrane flutdity in ox-brain phosphohpid hposomes: their order of effectiveness is, 4-hydroxytamox- 
ifen > 17/I-oestradiol > tamoxtfen > cis-tamoxifen > IV-desmethyltamoxifen > cholesterol. A good positrve correlation was demonstrated between 
the decrease m membrane fluidity by these compounds and their antioxidant ability as inhibitors of liposomal and mrcrosomal lipid peroxrdatton 
(correlation coefficient, r = 0.99. P c 0.001, in both cases). The ability of tamoxtfen to decrease membrane fluidity is suggested to be the mechanism 
of its antioxidant action and is discussed in relation to its anticancer and cardioprotecttve actions. 
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1. INTRODUCTION 
Tamoxifen is used widely and effectively in the treat- 
ment of breast cancer [14]. Indeed, it is now being 
assessed in clinical trials as a prophylactic agent against 
this disease [5-91. It is also being used to treat cancers 
of the liver [lo], brain [ 11,121 and pancreas [ 131 and may 
have general application in the prevention and treat- 
ment of cancer [14]. It is of considerable interest that 
tamoxifen and related compounds are membrane anti- 
oxidants; they inhibit metal ion-dependent lipid peroxi- 
dation in a range of membrane systems [15-171. Fur- 
thermore, tamoxifen and 4-hydroxytamoxifen protect 
human LDL against oxidative damage [18]. It has been 
suggested that tamoxifen and related compounds may 
act as membrane antioxidants by stabilising the mem- 
brane against lipid peroxidation through a mechanism 
involving a decrease in membrane fluidity [16]. Indeed, 
it has been reported previously that tamoxifen and 
17 /I-oestradiol decrease membrane fluidity, as judged 
by the rotation of fluorescent probe molecules, in two 
breast cancer cell-lines [ 191. 
In order to test our hypothesis, we determined the 
ability of tamoxifen, its cis isomer, its 4-hydroxy and 
N-desmethyl metabolites, 17 b-oestradiol and cholest- 
erol (structures shown in Fig. 1) to decrease membrane 
fluidity. A model membrane system consisting of li- 
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posomes formed from ox-brain phospholipid dispersed 
in aqueous medium was the experimental system used. 
Fluidity was measured using the fluorescent probe 
diphenylhexatriene (DPH) [20,21] and its phosphati- 
dylcholine derivative (DPH-PC) [21] and the results 
were correlated with the known membrane antioxidant 
abilities of these compounds in microsomes [15] and 
preformed liposomes. 
2. MATERIALS AND METHODS 
2.1. Chemicals 
Tamoxifen, cholesterol, 17 /I-oestradiol, ox-brain phospholiprds 
and DPH were from Sigma (Poole. Dorset, UK). 4-Hydroxytamox- 
ifen, cis-tamoxifen and N-desmethyltamoxifen were from ICI Pharma- 
ceuticals p.1.c. (Macclesfield, Cheshire. UK). DPH-PC was from Mo- 
lecular Probes Inc (Eugene, OR, USA). All other compounds were 
of Analar quality from BDH. 
2.2. Preparation of hposomes 
Ox-brain phospholipid liposomes were prepared as follows. The 
phospholiprd was added to phosphate-buffered saline (PBS) pH 7.4 
(140 mM NaCl, 2.7 mM KCl, 16 mM NaZHPO,, 2.9 mM KH?PO,) 
at a final concentratton of 5 mg/ml followed by vortexmg in the 
presence of glass beads (2.553.5 mm in diameter) at 20°C. The result- 
ing hposomes were left m sealed nitrogen-flushed bottles for 1 h before 
use 
2.3. Fluorescence measurements 
Incubatron mixtures contained (in a final volume of 3 ml) 1.5 ml of 
distilled water. 1.2 ml of PBS pH 7.4, and 0.3 ml of ox-brain phospho- 
liptd liposomes at a final concentration of phospholipid of 0.3 mM. 
Tamoxifen and related compounds. 17 /%oestradiol or cholesterol 
were each added m ethanol to give final concentrattons m the range 
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O-45 PM. at a final concentration of ethano! of 0.5% (v/v). Controls 
using this concentration of ethanol were always included as control 
treatments for the experiments. DPH dissolved in ethanol was added 
to give a final concentration of 1 PM. Incubation prior to fluorescence 
measurements was for 1 h at 20°C to ensure distribution of com- 
pounds and probe m the phosphohpid bllayers. 
In experiments where DPH-PC was used as the probe a direrent 
approach to preparation was taken to ensure that the probe was 
distributed throughout the phosphohpld bllayers because unlike DPH. 
DPH-PC becomes intercalated between the phosphohpids in the belay- 
ers [21]. DPH-PC was added in ethanol to the ox-brain phosphohpid 
(dissolved m chloroform) to give a final concentration m the liposome 
suspension of 1 PM; the solvents were completely evaporated under 
a stream of oxygen-free dry nitrogen and hposomes were prepared as 
described above. 
The excitation (8 nm slit) and emission (8 nm slit) wavelengths were 
348 nm and 428 nm. respectively for DPH. and 362 nm and 433 nm 
for DPH-PC. All fluorescence measurements were performed at a 
temperature of 20 f 1°C using a Perkin-Elmer MPF 44A spec- 
trofluonmeter. Polarizers were mounted on the excitation and emls- 
Sian sides of the sample cuvette and measurements of fluorescence 
intensity were made with the polarizers m parallel (I,,) and perpendlc- 
ular (IL) configurations, respectively. Values for the fluorescence ani- 
sotropy ratio, A [20.21] were calculated. 
The addition of tamoxlfen and related compounds to ox-bram phos- 
phohpld liposomes (prepared as described above), subsequent peroxi- 
datlon by Fe(III)-ascorbate and measurement of the extent of peroxi- 
dation by the thiobarblturic acid (TBA) test were as described m 
previously for rat hver microsomes [15]. with the exception that the 
reactlons were terminated by the addition of 100,~l of BHT (butylated 
hydroxytoluene: 0.2% w/v) dissolved in ethanol to suppress further 
peroxidatIon during the heating stage of the TBA reaction. Graphs 
plotted from these results were used to obtam the ICzs values for 
mhlbltlon of hposomal and microsomal hpld perowldatlon used for 
purposes of comparison (m Table 1) and correlation with those for 
decreased membrane flmdity. 
3. RESULTS 
Tamoxifen. 4-hydroxytamoxifen, N-desmethylta- 
moxifen, cis-tamoxifen, 17 P-oestradiol and cholesterol 
were each added to the ox-brain phospholipid li- 
posomes in ethanol (ethanol itself at the concentration 
used had no effect on membrane fluidity) to give final 
concentrations in the range O-45 PM at a final concen- 
tration of phospholipid of 0.3 mM. Fig. 2 shows that 
these compounds all decreased membrane fluidity (in- 
creased the fluorescence anisotropy ratio. A) in a con- 
centration-dependent manner and that 4-hydroxyta- 
moxifen and 17 P-oestradiol were more effective at 
decreasing membrane fluidity than tamoxifen, whereas 
N- desmethyltamoxifen and cis-tamoxifen were less ef- 
fective. In addition, cholesterol itself was found to dis- 
play only a poor ability to decrease membrane fluidity; 
at 45 ,uM an increase in A of only 7 k 4.1% (S.E.M., 
n = 3) was found with this approach. When DPH-PC (1 
PM) was used as the probe tamoxifen and 4-hydroxyta- 
moxifen (both at a concentration of 45 PM) increased 
A by 22 + 2.4% (S.E.M., n = 3) and 36 k 4.1% (S.E.M., 
n = 3), respectively compared to 25 + 2.8% (S.E.M., 
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Fig. 1 Structures of tamoxlfen. related compounds and 17 p-oestra- 
dlol and cholesterol. Structural similarity of the triphenylethylene 
compounds to cholesterol and 17 ,&oestradiol. 
y1= 3) and 34 + 4.9% (S.E.M., n = 3) when DPH (1 yM) 
was the probe used (see Fig. 2). The differences in the 
potency of these compounds to decrease membrane flu- 
idity (increase the fluorescence anisotropy ratio, A) are 
reflected in their ICz5 values (see Table I: ICzs rather 
than IC,, values were calculated because none of the 
compounds, over the concentration range used. in- 
creased A by as much as 50%). 
Fig. 2 and Table I show that the order of effectiveness 
of these compounds in decreasing membrane fluidity is 
4-hydroxytamoxifen > 17 /?-oestradiol > tamoxifen > 
cis-tamoxifen > N-desmethyltamoxifen > cholesterol. 
Fig. 3 shows that a good positive correlation was found 
between the IC,, values for decreased membrane fluid- 
ity and the IC,, values for the inhibition of liposomal 
and microsomal lipid peroxidation (correlation coeffi- 
cient, r = 0.99. P < 0.001, in both cases). 
4. DISCUSSION 
Our results show that tamoxifen, cis-tamoxifen, 4- 
hydroxytamoxifen, N-desmethyltamoxifen. 17 p-oestra- 
diol and cholesterol all decreased membrane fluidity in 
ox-brain phospholipid liposomes and that their order of 
effectiveness was 4-hydroxytamoxifen > 17 /?-oestra- 
diol > tamoxifen > cis-tamoxifen > N-desmethyltamox- 
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Fig. 2. Concentration-dependent increase in fluorescence amsotropy 
ratios. A, measured using DPH (1 ,BM) as the probe, by (0) tamoxifen, 
(m) 4-hydroxytamoxtfen, (0) crs-tamoxifen, (0) N-desmethyltamox- 
ifen, or (A) 17 jI-oestradiol, all in the range 045 ,uM. Results are 
shown as mean + S.E.M.. n = 3 
ifen > cholesterol (see Fig. 2 and Table I). This order 
parallels their antioxidant ability as inhibitors of lipo- 
somal and microsomal lipid peroxidation and is re- 
flected in the good positive correlation coefficients 
(r = 0.99, P < 0.001, in both cases: see Fig. 3) between 
the two parameters. 
The relatively poor ability of cholesterol to decrease 
membrane fluidity reflected also in its weak antioxidant 
activity may reflect the use of a lipid substrate rich in 
polyunsaturated fatty acid side-chains. The well-recog- 
nized ability of cholesterol to stabilize membranes is 
thought to occur via an interaction between the rigid 
hydrophobic ring structure of cholesterol and the satu- 
rated, mono-unsaturated, and to a much lesser extent 
the poly-unsaturated, fatty acid side-chains of 
phospholipids, which decreases membrane fluidity [22]. 
Examination of the chemical structure of tamoxifen (see 
Fig. 1) indicates that it is unlikely to act chemically as 
a chain-breaking antioxidant (no potentially donatable 
hydrogen atom, such as a phenolic hydrogen) and in- 
deed neither it nor its 4-hydroxy metabolite show the 
kinetics characteristic of such an antioxidant mecha- 
nism [16]. The present results clearly establish a mem- 
brane stabilizing action against lipid peroxidation via 
decreased membrane fluidity by tamoxifen and related 
compounds, which share a structural similarity with 
cholesterol [23] as the mechanism of their antioxidant 
action. 
The close agreement between the results for tamox- 
ifen and 4-hydroxytamoxifen with the two probes, DPH 
and DPH-PC, reflect a consistency of the effects on 
membrane fluidity in two different domains within the 
membrane lipid bilayer reported by the respective 
probes. Moreover, these findings are in agreement with 
a previous study using DPH as the fluorescent probe 
[19] that reported that although in the oestrogen recep- 
tor-positive MCF-7 cell-line tamoxifen (at 1 PM and 10 
,uM) decreased membrane fluidity more effectively than 
17 P-oestradiol at the same concentrations, in the 
oestrogen receptor-negative MDA-MD-436 cell-line 17 
/?- oestradiol was more effective than tamoxifen (as 
found in our liposomal study). Perhaps in the oestro- 
gen-receptor positive cells a decreased amount of 17 
P-oestradiol was present in the membrane lipid bilayer 
because of its preferential binding to the oestrogen re- 
ceptor. 
It is noteworthy that some metastatic cancer cells 
have been reported to show increased membrane fluid- 
ity [24] that could thus be counteracted by this ability 
of tamoxifen to decrease membrane fluidity. This effect 
of tamoxifen could also contribute to its anticancer ac- 
tion by inhibiting the action of membrane enzymes, 
receptors and channels such as adenylate cyclase, the 
activity of which has been shown to decrease with de- 
creased membrane fluidity [25]. This could lead to de- 
creased levels of cellular CAMP levels thereby causing 
inhibition of the growth of some cancer cells [26]. 
We have recently reported that tamoxifen and in par- 
Table I 
lCzr values for the inhibition of microsomal and liposomal hpid perox- 
idation and for the increase in the fluorescence anisotropy ratio, A, 
indicating decreased membrane fluidity by tamoxifen and related com- 
pounds 
Compound 
Membrane 
fluidity 
@M) 
IC,, 
Lipid peroxidation 
Microsomes Liposomes 
@M)** t&M)*** 
Tamoxifen 45 8 7 
4-Hydroxytamoxtfen 36 2 2 
17 B-Oestradiol 40 5 4 
crs-Tamoxifen 48 11 9 
N-Desmethyltamoxifen 53 14 11 
Cholesterol NR NR NR 
*Values are deduced from the graphs shown in Fig. 2 m which each 
pomt represents the mean ? S.E.M. of three separate experiments. 
**Values are deduced from the graphs shown m [15]. 
***Values are deduced from graphs, not shown (H. Wiseman, unpub- 
lished data). 
NR, not reached. ICzs was the concentration (in PM) of each com- 
pound required to either inhibit microsomal or liposomal lipid perox- 
idation or to decrease membrane fluidity (increase the fluorescence 
anisotropy ratio. A) by 25%. 
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Fig. 3. Correlation between the I& values for decreased membrane 
flutdity (increase in the fluorescence anisotropy ratio. A) and inhibt- 
non of liposomal lipid peroxtdation by (0) tamoxifen. (w) 4-hy- 
droxytamoxifen, (0) cis-tamoxtfen, (0) N-desmethyltamoxtfen and (A) 
17 B-oestradiol. 
ticular 4-hydroxytamoxifen protect human LDL 
against oxidative damage [ 181 and that this may contrib- 
ute to the observed cardiovascular benefits of tamoxifen 
therapy [27-301. We proposed that these compounds 
may stabilize LDL against peroxidation by interaction 
between their hydrophobic rings and the polyunsatu- 
rated residues of the phospholipid layer of LDL. This 
is supported by the decreased membrane fluidity arising 
from similar interactions in liposomal membranes, 
measured in the present study. 
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